Literature DB >> 21293300

Loss of chromosome 1p/19q in oligodendroglial tumors: refinement of chromosomal critical regions and evaluation of internexin immunostaining as a surrogate marker.

Patrick G Buckley1, Leah Alcock, Josephine Heffernan, Jack Woods, Francesca Brett, Raymond L Stallings, Michael A Farrell.   

Abstract

Loss of chromosome 1p/19q in oligodendrogliomas represents a powerful predictor of good prognosis. Expression of internexin (INA), a neuronal specific intermediate filament protein, has recently been proposed as a surrogate marker for 1p/19q deletion based on the high degree of correlation between both parameters in oligodendrogliomas. The aim of this study was to assess further the diagnostic utility of INA expression in a set of genetically well-characterized oligodendrogliomas. On the basis of a conservative approach for copy number determination, using both comparative genomic hybridization and fluorescent in situ hybridization, INA expression as a surrogate marker for 1p/19q loss had both reduced specificity (80%) and sensitivity (79%) compared with respective values of 86% and 96% reported in the previous report. The histologic interpretation and diagnostic value of INA expression in oligodendrogliomas should therefore be assessed with greater caution when compared with 1p/19q DNA copy number analysis. In addition, DNA copy number aberrations of chromosomes 10, 16, and 17 were detected exclusively in 1p/19q codeleted samples, suggesting that other regions of the genome may contribute to the 1p/19q-deleted tumor phenotype inthese samples.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21293300     DOI: 10.1097/NEN.0b013e31820c765b

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  8 in total

1.  The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas.

Authors:  Craig Horbinski; Marina N Nikiforova; Jonathan Hobbs; Stephanie Bortoluzzi; Kathleen Cieply; Sanja Dacic; Ronald L Hamilton
Journal:  J Neuropathol Exp Neurol       Date:  2012-01       Impact factor: 3.685

Review 2.  Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.

Authors:  Alexandra McAleenan; Hayley E Jones; Ashleigh Kernohan; Tomos Robinson; Lena Schmidt; Sarah Dawson; Claire Kelly; Emmelyn Spencer Leal; Claire L Faulkner; Abigail Palmer; Christopher Wragg; Sarah Jefferies; Sebastian Brandner; Luke Vale; Julian Pt Higgins; Kathreena M Kurian
Journal:  Cochrane Database Syst Rev       Date:  2022-03-02

Review 3.  Oligodendroglioma: pathology, molecular mechanisms and markers.

Authors:  Pieter Wesseling; Martin van den Bent; Arie Perry
Journal:  Acta Neuropathol       Date:  2015-05-06       Impact factor: 17.088

4.  Automated Analysis of 1p/19q Status by FISH in Oligodendroglial Tumors: Rationale and Proposal of an Algorithm.

Authors:  Céline Duval; Marie de Tayrac; Karine Michaud; Florian Cabillic; Claudie Paquet; Peter Vincent Gould; Stéphan Saikali
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

5.  Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.

Authors:  Yan-Xi Li; Zhifeng Shi; Abudumijiti Aibaidula; Hong Chen; Qisheng Tang; Kay Ka-Wai Li; Nellie Yuk-Fei Chung; Danny Tat-Ming Chan; Wai Sang Poon; Ying Mao; Jinsong Wu; Liangfu Zhou; Aden Ka-Yin Chan; Ho-Keung Ng
Journal:  Oncotarget       Date:  2016-10-04

6.  Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.

Authors:  J S Frenel; C Leux; D Loussouarn; A-G Le Loupp; F Leclair; M Aumont; A Mervoyer; S Martin; M G Denis; M Campone
Journal:  J Neurooncol       Date:  2013-05-17       Impact factor: 4.506

7.  A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.

Authors:  Nayuta Higa; Toshiaki Akahane; Seiya Yokoyama; Hajime Yonezawa; Hiroyuki Uchida; Tomoko Takajo; Mari Kirishima; Taiji Hamada; Kei Matsuo; Shingo Fujio; Tomoko Hanada; Hiroshi Hosoyama; Masanori Yonenaga; Akihisa Sakamoto; Tsubasa Hiraki; Akihide Tanimoto; Koji Yoshimoto
Journal:  Cancer Sci       Date:  2020-09-06       Impact factor: 6.716

8.  Expression of TCF7L2 in Glioma and Its Relationship With Clinicopathological Characteristics and Patient Overall Survival.

Authors:  Shiyuan Jing; Lei Chen; Song Han; Ning Liu; MingYang Han; Yakun Yang; Changxiang Yan
Journal:  Front Neurol       Date:  2021-07-08       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.